PPH - VanEck Vectors Pharmaceutical ETF

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
61.76
+0.53 (+0.87%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close61.23
Open61.23
Bid60.53 x 1300
Ask63.09 x 800
Day's Range61.23 - 61.80
52 Week Range54.44 - 64.90
Volume105,478
Avg. Volume33,335
Net Assets276.05M
NAV64.37
PE Ratio (TTM)N/A
Yield1.58%
YTD Return9.74%
Beta (3Y Monthly)0.81
Expense Ratio (net)0.35%
Inception Date2011-12-20
Trade prices are not sourced from all markets
  • Novartis’ Estimates and Recommendations on October 12
    Market Realist21 hours ago

    Novartis’ Estimates and Recommendations on October 12

    Wall Street analysts estimate that Novartis (NVS) will report revenues of $13.02 billion for the third quarter of 2018, a 4.9% growth year-over-year compared to $12.41 billion. Novartis stock has decreased ~4.9% over the last 12 months. As of October 12, there are two analysts tracking Novartis ADR (American Depositary Receipts).

  • Novartis: What to Expect from Q3 Earnings on October 18
    Market Realistyesterday

    Novartis: What to Expect from Q3 Earnings on October 18

    Novartis (NVS) is set to release its third quarter of 2018 earnings results on October 18. Analysts are estimating EPS of $1.31 and revenues of $13.02 billion. Novartis, one of the largest pharmaceutical companies by revenue, specializes in the development, manufacturing, and marketing of healthcare products.

  • An Update on Bausch + Lomb/International in October
    Market Realistyesterday

    An Update on Bausch + Lomb/International in October

    Bausch + Lomb/International, a subsidiary of Bausch Health (BHC), generated net revenues of $1.21 billion in the second quarter, compared to $1.22 billion in the second quarter of 2017. This increase reflects ~4.0% YoY (year-over-year) organic growth. 

  • Investopedia4 days ago

    Top 5 Pharmaceutical ETFs for 2018

    The healthcare sector will continue to see political attention in the remainder of 2018, with the 2017 U.S. tax reform bill influencing it in a number of ways. Its repeal of mandated healthcare is likely to change demand and effect provider participation.

  • A Look at Novartis’s Valuation on October 9
    Market Realist7 days ago

    A Look at Novartis’s Valuation on October 9

    Novartis AG (NVS) reported EPS of $1.29 on revenue of $13.2 billion in the second quarter, reporting a 7% YoY (year-over-year) rise in revenue compared to $12.2 billion in the second quarter of 2017.

  • GW Pharmaceuticals: Q3 Performance, Q4 Estimates
    Market Realist11 days ago

    GW Pharmaceuticals: Q3 Performance, Q4 Estimates

    GW Pharmaceuticals (GWPH) is a leader in the development of plant-derived cannabinoid therapeutics. GW Pharmaceuticals reported EPS of -$1.26 on revenues of $3.46 million in the third quarter. It was a 10.2% revenue growth year-over-year.

  • Business Wire18 days ago

    Announcing VanEck Vectors Equity ETFs’ September 2018 Distributions

    VanEck announced today its regular distributions per share for the VanEck Vectors® equity exchange-traded funds.

  • Why Bausch Health Stock Is Soaring Today
    Market Realistlast month

    Why Bausch Health Stock Is Soaring Today

    Bausch’s current stock price is ~18% lower than the 52-week high of $27.79 it saw on June 13. Bausch hit its 52-week low of $10.94 on November 2, 2017. Today, Bausch Health’s wholly owned subsidiary Salix Pharmaceuticals and its licensors Cedars-Sinai Medical Center and Alfasigma announced that they’d agreed to resolve pending intellectual property litigation associated with the drug Xifaxan with Actavis Laboratories.

  • Investopedia2 months ago

    Top 5 Pharmaceutical ETFs for 2018

    The healthcare sector will continue to see political attention in the remainder of 2018, with the 2017 U.S. tax reform bill influencing it in a number of ways. Its repeal of mandated healthcare is likely to change demand and effect provider participation.

  • Merck Witnessed 5% Growth in Q2 2018
    Market Realist3 months ago

    Merck Witnessed 5% Growth in Q2 2018

    Merck (MRK) reported its second-quarter earnings on July 27. Merck generated revenues of $10.5 billion in the second quarter, reflecting ~5.0% year-over-year (or YoY) growth. In the second quarter, Merck’s Pharmaceuticals segment generated revenues of $9.3 billion compared to $8.8 billion in the second quarter of 2017, reflecting ~6.0% YoY growth. Merck’s Animal Health segment generated revenues of $1.1 billion in the second quarter, reflecting ~14.0% YoY growth.

  • ETF Trends3 months ago

    July Could Be a Volatile Month for Pharma ETFs

    Changing political winds and the seasonal period for drugmakers to hike their prices could trigger short-term volatility in pharmaceutical sector-related ETFs. The markets could put a spotlight on pharmaceutical stocks and the rising cost of drug prices as Mid-term elections are quickly coming up in November and July is a popular month for drug companies to increase list prices on medicines, writes Charley Grant for the Wall Street Journal. Just last week, Health and Human Services Secretary Alex Azar said in congressional testimony that companies should “practice restraint” with price increases.

  • Business Wire4 months ago

    Announcing VanEck Vectors Equity ETFs June 2018 Distributions

    VanEck announced today its regular distributions per share for its VanEck Vectors® equity exchange-traded funds.

  • Pharmaceutical ETFs and Their Performances in May
    Market Realist4 months ago

    Pharmaceutical ETFs and Their Performances in May

    Pharmaceutical ETFs are securities that are publicly traded on the stock market and designed for investors wanting to diversify their investments in the pharmaceutical sector.

  • Biogen Inc Stock Got an Upgrade, but Should You Listen?
    InvestorPlace4 months ago

    Biogen Inc Stock Got an Upgrade, but Should You Listen?

    Generally speaking, pharmaceuticals are experiencing a mixed year. After a promising start where Biogen shares closed out January up more than 8%, the momentum quickly collapsed. It wasn’t until the prior month that BIIB stock began to recover from its mess.

  • How GlaxoSmithKline’s Segments Performed in Q1 2018
    Market Realist5 months ago

    How GlaxoSmithKline’s Segments Performed in Q1 2018

    GlaxoSmithKline’s (GSK) product portfolio is segregated into three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. GlaxoSmithKline reported a 2% YoY (year-over-year) fall in revenue to ~7.2 billion British pounds in Q1 2018 compared to Q1 2017.

  • How Merck’s Human Vaccines Business Performed in 1Q18
    Market Realist5 months ago

    How Merck’s Human Vaccines Business Performed in 1Q18

    In 1Q18, Merck’s (MRK) human vaccines business saw its total revenue grow 4.2% YoY (year-over-year) to $1.5 billion from $1.4 billion. Its Gardasil franchise includes vaccines used to prevent strains of sexually transmitted HPV (human papillomavirus) infections that cause genital warts and have been linked with cervical, vulvar, anal, penile, and vaginal cancer. 

  • Merck and AstraZeneca Announced EMA Approval for Lynparza
    Market Realist5 months ago

    Merck and AstraZeneca Announced EMA Approval for Lynparza

    Lynparza (olaparib) is a poly(ADP-ribose) polymerase inhibitor, or PARP inhibitor, and part of Merck & Co. (MRK) and AstraZeneca’s (AZN) global strategic oncology collaboration.

  • GlaxoSmithKline’s 1Q18 Earnings: Performance by Segment
    Market Realist6 months ago

    GlaxoSmithKline’s 1Q18 Earnings: Performance by Segment

    GlaxoSmithKline’s (GSK) product portfolio is divided into three business segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. GlaxoSmithKline reported revenues of ~7.2 billion pounds in 1Q18, a ~2% decline compared to 1Q17. However, all three segments reported growth in operating revenues in 1Q18.

  • Sanofi Misses Wall Street Estimates for 1Q18 Revenues
    Market Realist6 months ago

    Sanofi Misses Wall Street Estimates for 1Q18 Revenues

    Sanofi (SNY) missed Wall Street analysts’ estimates for revenues today but beat estimates for earnings per share (or EPS). It reported EPS of 1.28 euros on revenues of ~7.9 billion euros, compared to estimates for EPS of 1.13 euros on revenues of 8.1 billion euros for 1Q18.

  • What Wall Street Analysts Estimate for Johnson & Johnson
    Market Realist6 months ago

    What Wall Street Analysts Estimate for Johnson & Johnson

    Johnson & Johnson (JNJ) surpassed EPS (earnings per share) and revenue estimates in 1Q18. For 1Q18, Johnson & Johnson reported EPS of $2.06 on revenues of $20.0 billion during 1Q18 against the estimates for EPS of $2.00 on revenues of $19.4 billion during 1Q18.

  • GlaxoSmithKline: Operating Revenues Up in 1Q18 Earnings
    Market Realist6 months ago

    GlaxoSmithKline: Operating Revenues Up in 1Q18 Earnings

    GlaxoSmithKline (GSK) beat Wall Street analysts’ estimates for earnings per share (or EPS) and revenues for 1Q18. The above chart compares the quarterly revenues and EPS for GlaxoSmithKline since 1Q17. GlaxoSmithKline reported revenues of 7.2 billion pounds in 1Q18, a 2% decline in revenues, compared to 7.4 billion pounds in 1Q17.

  • Analysts’ Estimates for Sanofi’s 1Q18 Earnings
    Market Realist6 months ago

    Analysts’ Estimates for Sanofi’s 1Q18 Earnings

    Paris-headquartered Sanofi (SNY), one of the world’s largest pharmaceutical companies, reports its financial results in euros. The company is set to release its 1Q18 earnings on April 27. Analysts expect Sanofi to report EPS (earnings per share) of 1.13 euros and revenue of 8.1 billion euros.

  • Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
    Zacks6 months ago

    Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?

    Sector ETF report for PPH

  • Analysts’ Recommendations for Eli Lilly & Co. on April 20
    Market Realist6 months ago

    Analysts’ Recommendations for Eli Lilly & Co. on April 20

    Eli Lilly & Co. (LLY) surpassed Wall Street analysts’ estimates for earnings per share (or EPS) and revenues during 4Q17. The company reported EPS of $1.14 on revenues of ~$6.2 billion, compared to the estimated EPS of $1.07 on revenues of ~$5.9 billion. Analysts expect the company to report EPS of $1.14 on revenues of $5.5 billion during 1Q18.